id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-N-0093-0016,FDA,FDA-2013-N-0093,Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals,Notice,Notice of Approval,2022-10-28T04:00:00Z,2022,10,2022-10-28T04:00:00Z,,2022-10-28T18:57:11Z,2022-23510,0,0,0900006485462fa0
FDA-2013-N-0093-0015,FDA,FDA-2013-N-0093,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Review Transparency and Communication for New Molecular Entity New Drug Applications and Original Biologics License Applications in Prescription
Drug User Fee Submissions",Notice,30 Day Proposed Information Collection,2022-08-29T04:00:00Z,2022,8,2022-08-29T04:00:00Z,2022-09-29T03:59:59Z,2022-08-29T19:29:38Z,2022-18546,0,0,09000064852853f4
FDA-2013-N-0093-0014,FDA,FDA-2013-N-0093,"Agency Information Collection Activities; Proposed Collection; Comment Request; New Molecular Entity New Drug Applications and Original Biologics License 
Applications",Notice,60 Day Proposed Information Collection,2022-03-21T04:00:00Z,2022,3,2022-03-21T04:00:00Z,2022-05-21T03:59:59Z,2022-08-29T19:25:19Z,2022-05814,0,0,0900006484fd6a0a
FDA-2013-N-0093-0013,FDA,FDA-2013-N-0093,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals",Notice,Information Collection Request (ICR),2019-11-07T05:00:00Z,2019,11,2019-11-07T05:00:00Z,,2019-11-07T15:05:12Z,2019-24263,0,0,090000648412882c
FDA-2013-N-0093-0012,FDA,FDA-2013-N-0093,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Review  Transparency and Communication in Reviews of 351(k) Biologics License
Applications in Biosimilars User Fee Act",Notice,30 Day Proposed Information Collection,2019-08-19T04:00:00Z,2019,8,2019-08-19T04:00:00Z,2019-09-19T03:59:59Z,2019-08-19T12:57:43Z,2019-17713,0,0,0900006483e6b73f
FDA-2013-N-0093-0011,FDA,FDA-2013-N-0093,Agency Information Collection Activities; Proposed Collection; Comment Request; Review Transparency and Communication in Reviews of 351(k) Biologics License Applications in Biosimilars User Fee Act,Notice,60 Day Proposed Information Collection,2019-03-12T04:00:00Z,2019,3,2019-03-12T04:00:00Z,2019-05-14T03:59:59Z,2019-07-29T17:42:10Z,2019-04429,0,0,0900006483ad6852
FDA-2013-N-0093-0010,FDA,FDA-2013-N-0093,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Announcement of Office of Management and Budget Approvals",Notice,Notice of Approval,2016-12-19T05:00:00Z,2016,12,2016-12-19T05:00:00Z,,2016-12-19T15:47:08Z,2016-30351,0,0,09000064824264d4
FDA-2013-N-0093-0007,FDA,FDA-2013-N-0093,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Evaluation of the
Program for Enhanced Review Transparency and Communication for
New Molecular Entity New Drug Applications and Original Biologics
License Applications in Prescription Drug User Fee Acts",Notice,30 Day Proposed Information Collection,2016-07-21T04:00:00Z,2016,7,2016-07-21T04:00:00Z,2016-08-23T03:59:59Z,2016-08-23T01:02:01Z,2016-17185,0,0,09000064820db4f9
FDA-2013-N-0093-0006,FDA,FDA-2013-N-0093,"Agency Information Collection Activities: Proposed Collection;
Comment Request; Evaluation of the Program for Enhanced Review
Transparency and Communication for New Molecular Entity New Drug
Applications and Original Biologics License Applications in Prescription
Drug User Fee Acts",Notice,60 Day Proposed Information Collection,2015-12-10T05:00:00Z,2015,12,2015-12-10T05:00:00Z,2016-02-09T04:59:59Z,2015-12-10T17:15:29Z,2015-31100,0,0,0900006481d9ab7a
FDA-2013-N-0093-0004,FDA,FDA-2013-N-0093,Meetings: Interim Assessment of the Program for Enhanced Review Transparency and Communication,Notice,Meeting,2015-04-22T04:00:00Z,2015,4,2015-04-22T04:00:00Z,2015-07-01T03:59:59Z,2015-06-25T01:30:38Z,2015-09300,0,0,0900006481ab3685
FDA-2013-N-0093-0002,FDA,FDA-2013-N-0093,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Evaluation of the Program for Enhanced Review Transparency and Communication for New Molecular Entity New Drug Applications and Original Biologics License Applications in Prescription Drug User Fee Act,Notice,30 Day Proposed Information Collection,2013-05-08T04:00:00Z,2013,5,2013-05-08T04:00:00Z,,2015-11-19T19:44:10Z,2013-10898,0,0,09000064812c4599
FDA-2013-N-0093-0001,FDA,FDA-2013-N-0093,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Molecular Entity New Drug Applications and Original Biologics License Applications in Prescription Drug User Fee Act",Notice,60 Day Proposed Information Collection,2013-02-19T05:00:00Z,2013,2,2013-02-19T05:00:00Z,2013-04-23T03:59:59Z,2024-11-07T22:49:06Z,2013-03705,1,0,09000064811fd0b1